Natalia Fanani, PA
Medical · Norwich, CTNPI 1164124657
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,555 of the $6,803 with a category attached, or 81.7%. It is spread thinly across 38 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $27.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$1K
- AstraZeneca$656
- Pfizer$579
- AbbVie$400
- Novo Nordisk$393
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$297
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$1,05015%
- Food & beverage$5,55582%
- Education$1983%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 9 | $1,220 |
| AstraZeneca | 19 | $656 |
| Pfizer | 29 | $579 |
| AbbVie | 28 | $400 |
| Novo Nordisk | 23 | $393 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $297 |
| Johnson & Johnson | 9 | $280 |
| GSK | 12 | $275 |
| Regeneron Healthcare Solutions, Inc. | 6 | $255 |
| Merz North America, Inc. | 4 | $224 |
| Lilly USA, LLC | 7 | $197 |
| Astellas Pharma US Inc | 11 | $183 |
| LEO Pharma Inc. | 7 | $169 |
| Lundbeck LLC | 6 | $163 |
| UCB, Inc. | 5 | $153 |
| Boehringer Ingelheim | 7 | $144 |
| Sanofi | 4 | $123 |
| Novartis | 4 | $109 |
| Corcept Therapeutics | 4 | $102 |
| Galderma Laboratories, L.p. | 5 | $101 |
| Sumitomo Pharma America, Inc. | 4 | $100 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $72 |
| Amgen | 3 | $70 |
| Mayne Pharma Commercial LLC | 8 | $68 |
| Incyte Corporation | 2 | $60 |
| Neurocrine Biosciences, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Verrica Pharmaceuticals Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Botanix SB Inc | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Organon | 2 | $24 |
| LNHC, Inc | 1 | $23 |
| Exact Sciences | 1 | $20 |
| Biofrontera Inc. | 1 | $20 |
| Arcutis Biotherapeutics, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,803 in reported general payments places this provider in the 90th percentile of 592 medical providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 92 | $95,094 |
| JardianceEmpagliflozin | 53 | $61,318 |
| MounjaroTirzepatide | 38 | $49,211 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $47,233 |
| JanuviaSitagliptin Phosphate | 22 | $27,674 |
| GemtesaVibegron | 36 | $25,183 |
| EliquisApixaban | 21 | $21,126 |
| MyrbetriqMirabegron | 23 | $17,888 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,022 |
| PremarinEstrogens, Conjugated | 13 | $4,159 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,820 |
| SynthroidLevothyroxine Sodium | 38 | $3,277 |
| Atorvastatin Calcium | 254 | $2,752 |
| Levothyroxine Sodium | 291 | $2,440 |
| Omeprazole | 132 | $1,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $393 | $95,09492 claims |
| Boehringer IngelheimJardiance | $144 | $61,31853 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $275 | $54,25467 claims |
| Lilly USA, LLCMounjaro | $197 | $49,21138 claims |
| PfizerEliquis, Premarin | $579 | $25,28534 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $100 | $25,18336 claims |
| Astellas Pharma US IncMyrbetriq | $183 | $17,88823 claims |
| AbbVieSynthroid | $400 | $3,27738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 592 medical providers in Connecticut.
Other medical in Norwich
- Jaclyn NeveuNorwich$8K
- Shilpa DesaiStamford$215K
- Gregory RauNew Haven$211K
- John JasinskiNorwalk$185K
- Brianna PaesanoStamford$153K
- Debra SullivanDerby$100K
- Ryan DonovanNew Haven$75K
- Jonica PagnuccoWaterbury$32K
- Alyssa GreenleafSouthington$26K
- Mark VolpeSuffield$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.